Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Misconceptions about the use of biosimilars

Laszlo Gulacsi • 14 Jun 2017
ICML 2017
Antibodies Rituximab

Laszlo Gulacsi, MD, PhD from Corvinus University Budapest, Budapest, Hungary discusses misconceptions about the use of biosimilars such as rituximab. Prof. Gulasci mentions that not all physicians are well-informed on this topic as some associate risks with the use of biosimilars. However, as he explains, switching studies have shown that switching from an originator biological to a biosimilar does not lead to a worsening of disease.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

More from Laszlo Gulacsi

The potential of biosimilar rituximab: reducing budgets and increasing access to treatment
3:18
The potential of biosimilar rituximab: reducing budgets and increasing access to treatment
Laszlo Gulacsi • 14 Jun 2017

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals